Subscribe To

Price Alert Latest News Economic Calendar News

RVMD / Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a live fireside chat at the event. Read More

Demo Live Account See Partner Details

Content Topics

Revolution

Medicines

Participate

43rd

Annual

Goldman

Sachs

Global

Healthcare

Conference

Stock

RVMD

Posted: Jun 9 2022, 16:02

Author Name: GlobeNewsWire

RVMD News

By GlobeNewsWire
October 31, 2023

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel

By The Motley Fool
October 23, 2023

Why Revolution Medicines Stock Is Crashing Today

Revolution Medicines reported data from a phase 1 study of RMC-6236 in treating lung cancer and pancreatic cancer. High numbers of unconfirmed respons

By The Motley Fool
October 13, 2023

Why Shares of Revolution Medicines Were Popping on Friday

Revolution Medicines is a clinical-stage biotech. The company has nearly a million in cash to develop its deep pipeline.

By Seeking Alpha
September 25, 2023

Revolution Medicines: A Big Pipeline In Need Of Big Data

Revolution Medicines, Inc. has a diversified pipeline of drugs but is still searching for its flagship project, making it a high-risk investment. The

By Seeking Alpha
August 8, 2023

Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Erin Graves – Senior Direc

By Seeking Alpha
July 11, 2023

Revolution Medicines: Early-Stage Firm Whose High Valuation I Cannot Explain

Revolution Medicines, Inc. is undoubtedly doing interesting science. However, I can name 10 companies that are doing equally interesting science but a

By GlobeNewsWire
June 8, 2023

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing target

By Seeking Alpha
May 8, 2023

Revolution Medicines, Inc. (RVMD) Q1 2023 Earnings Call Transcript

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Erin Graves - Senior Director o

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.